IPO Window Meets a Liquidity Drain: $1.3B in New Listings, SpaceX Lockup Looms

The IPO calendar has suddenly filled. After a first half that saw U.S. IPO proceeds top $114 billion — led by SpaceX’s record $85.7 billion offering in June^[1] — the late-July window is now stacked with deals across biotech, consumer, and fashion. But the same week that bankers are pricing new issuance, the market’s plumbing is tightening: Treasury bill settlements are draining reserves, single-stock volatility is at a record premium to index vol, and the largest IPO in history is sliding toward its first lockup expiry.

This is a story about supply meeting liquidity at a moment when both are moving the wrong way.

The IPO calendar: three deals, three sectors, one week

The most consequential stretch of the U.S. IPO calendar since the SpaceX debut is underway:

Scribe Therapeutics (SCTX), an Eli Lilly-backed Phase 1 biotech developing CRISPR therapies for cardiovascular and metabolic diseases, set terms on July 20 for 7.15 million shares at $13–$15, targeting roughly $100 million in gross proceeds at the midpoint^[2]. The Alameda, California company expects net proceeds of about $96.2 million, or $110.2 million if underwriters exercise their overallotment option^[2]. The deal is notable as one of the few clinical-stage biotech IPOs to reach pricing in a year where biotech issuance has been selective.

Jersey Mike’s Subs (JMKE), the Blackstone-backed sandwich chain with over 3,000 U.S. locations, launched its roadshow on July 20 for 43.5 million shares at $21–$25, targeting approximately $1 billion in gross proceeds at the midpoint^[3]. The implied market cap ranges from $6.7 billion to $7.9 billion^[3]. Roughly 68% of the offering is secondary — selling shareholders could collect up to $742 million^[3]. The underwriting syndicate is one of the largest in recent memory, with 23 firms listed. The deal is expected to price on July 30 and list on the NYSE under JMKE^[4].

Reformation Inc. (REF), a Permira-backed sustainable womenswear brand, set terms the same day for 14.1 million shares at $15–$17, targeting up to $239.1 million and a valuation near $1 billion^[5]. The company reported $507.1 million in net revenue for 2025^[5]. Reformation is also expected to price July 30 and list on the NYSE under REF^[4].

The breadth matters. When the IPO window accommodates a CRISPR biotech, a franchise restaurant, and a DTC fashion brand in the same week, it signals that underwriters see enough investor appetite across sectors to fill the calendar. The question is whether that appetite survives the liquidity backdrop.

SpaceX lockup: the $123 billion overhang

The single largest supply event looming over the market is not a new IPO. It is the lockup expiry on SpaceX (SPCX) shares — and the timeline just got precise.

SpaceX announced on July 21 that its maiden earnings report will be released on August 4^[1]. That date triggers the company’s staggered lockup structure, which allows insiders to begin selling earlier than the typical 180-day period. On the second full trading day after the earnings release — August 6 — insiders become eligible to sell 20% of their locked-up stock, totaling up to 911.5 million shares^[1]. An additional 10% could unlock if the stock closes at least 30% above the $135 IPO price for five of the ten trading days leading into the report^[1].

As of Monday’s close, SpaceX shares had shed nearly half their value from the intraday high of $225.64 on June 16, and were down 43% from the all-time closing high of $211.39^[1]. The stock had been on a seven-day losing streak before snapping it with a 3% gain on Tuesday^[1]. The Globe and Mail reported that lockup restrictions are set to lift on approximately $123 billion worth of shares^[6].

The staggered structure is designed to prevent a flood of selling. But the early read is not reassuring: short interest has reached roughly a third of the public float, and Musk publicly warned short sellers on July 21^[1]. The stock’s slide below the IPO price of $135 means the additional 10% unlock condition is unlikely to trigger, which would cap the August 6 release at 20% — still a substantial block.

What would have to be true for the lockup to pass quietly? The stock would need to stabilize above recent lows through the earnings report, and the first tranche of sellers would need to find enough buy-side absorption. With only a small portion of shares currently trading freely, even moderate insider selling could produce outsized price impact. The August 4 earnings — the first look at SpaceX’s financials as a public company, including its Starlink revenue and the newly integrated SpaceXAI (formerly xAI) cloud-compute business — will set the tone^[1].

The liquidity backdrop: a summer drain

While issuance supply is rising, the liquidity that absorbs it is being pulled in the other direction.

Treasury bill settlements are expected to result in net new issuance of $56 billion beginning Tuesday July 22, followed by an additional $37 billion on Thursday and a smaller coupon settlement of $13 billion on Friday^[7]. Treasury bill issuance is expected to remain heavy through Labor Day, creating a sustained headwind for risk assets^[7].

The mechanism is straightforward: with the Federal Reserve’s reverse repo facility nearly depleted, new bill issuance now directly drains bank reserves rather than being absorbed by the repo market^[8]. One analysis estimates that net T-bill issuance will remove roughly $350 billion of liquidity by mid-September^[8]. Historically, T-bill settlement days have coincided with weaker equity performance^[8].

This drain arrives at a moment when the market’s internal structure is already stretched. The VIX has retreated below 18^[9], a level that conveys surface calm. But beneath that calm, single-stock volatility has jumped to a record premium over index volatility^[10]. Implied correlation has plumbed multi-decade lows^[10], meaning stocks are moving independently of each other rather than in tandem — a condition Goldman Sachs’ volatility desk flagged as a signal to seek hedging opportunities^[10].

The dispersion creates a paradox: index-level volatility looks benign, but the cost of hedging individual positions has rarely been higher. If the liquidity drain forces correlation higher — as Mott Capital’s analysis suggests it should^[7] — the dispersion trade that has worked for months would begin to unwind, and stocks would start moving in unison. That is the pattern that typically precedes a volatility regime shift.

Buybacks: a partial offset

On the demand side of the supply equation, buyback activity continues, though at a pace that does not fully offset the issuance and lockup supply:

• Jabil (JBL) announced a $1.5 billion share repurchase authorization on July 15^[11].
• Alimentation Couche-Tard (ATD.TO) renewed its repurchase program on July 16, authorizing up to 74.2 million shares (10% of public float)^[11].
• Wise Group (WISE) commenced a buyback program on July 21, with Goldman Sachs executing^[11].
• STMicroelectronics (STM) and Ahold Delhaize both reported ongoing repurchase activity for the week of July 13–17^[11].
• Ericsson (ERIC) reported buybacks for the same period^[11].

Buybacks provide a steady bid, but they are programmatic and spread across months. The supply events described here — a $1 billion IPO, a $225 million IPO, a $100 million biotech IPO, and up to 911.5 million SpaceX shares unlocking — are concentrated in a two-week window.

Recent IPO performance: the cautionary data

The performance of recently priced IPOs offers a sobering counterpoint to the optimism of a full calendar. Renaissance Capital’s recent pricing data shows mixed-to-poor results: QumulusAI (QMLS) is down 47.9% from its offer price, Standard Nuclear (STDN) is down 40.6%, and Csquare (CSQR) is roughly flat at -0.5%^[12]. SK hynix (SKHY), which priced on July 9 in one of the largest ADR offerings, is not yet showing return data but represents a different category of issuer entirely^[12].

The 2026 IPO class year-to-date has seen 86 IPOs priced, a 23.2% decline from the prior year^[12]. While the dollar value is elevated by the SpaceX mega-deal, the deal count is shrinking — a sign that the window is wide for large, brand-name issuers but narrow for smaller, less-established companies. Forge Global’s July pipeline update noted that “as pipeline fills, IPO performance remains uneven”^[13].

What to watch next

1. Scribe Therapeutics (SCTX) pricing — Thursday July 24. The first test of biotech appetite this week. A pricing at or above the $14 midpoint would signal risk tolerance for clinical-stage equity; a cut to the low end or postponement would be a warning.

2. Jersey Mike’s (JMKE) and Reformation (REF) pricing — Thursday July 30. Two consumer-sector deals on the same day. The JMKE deal size (~$1 billion) and its 68% secondary component make it the more significant test of buy-side depth. Watch for whether the syndicate can absorb the selling shareholder portion without pricing below the range.

3. SpaceX (SPCX) earnings — Monday August 4. The first public financial disclosure. Lockup release follows on August 6. The gap between the earnings reaction and the lockup trigger will determine whether insiders face a bid or a void.

4. Treasury bill settlement schedule. The $56 billion settling Tuesday, $37 billion Thursday, and $13 billion Friday are the near-term drains^[7]. Watch bank reserve levels and the RRP facility balance for signs that the drainage is accelerating or stabilizing.

5. Implied correlation and dispersion. If correlation begins rising from multi-decade lows alongside the liquidity drain, it would mark the early stages of a dispersion unwind — the pattern that historically precedes a volatility regime change.

The base case is that the IPO window remains open through the summer, supported by brand-name issuers and a still-functioning buyback bid. The risk case is that the convergence of rising supply (lockup expirations plus new issuance), falling liquidity (Treasury drainage), and stretched positioning (record dispersion at record low correlation) creates a tighter squeeze than any single indicator suggests. The next two weeks will show whether the window stays open — or whether the plumbing starts to groan.